Why Private Equity Firms Buy Insurance Companies: Strategic Depth

Quick Navigation

1. The Float Engine: Free Money to Invest

2. Tax Advantages That Make Deals Sweeter

3. Stable Cash Flows & Recession-Proof Earnings

4. Operational Leverage & Cost Synergies

5. The Risks Most Buyers Ignore

FAQ: Common Questions Answered

I've sat across the table from a dozen private equity partners who all claim they're buying an insurance company for the same reason: float. But that's only half the story. After digging through dozens of deals—from the disastrous to the wildly successful—I can tell you the real reasons are more nuanced. And some of them are anything but glamorous.Let's cut through the fluff. Private equity firms don't buy insurers because they love underwriting or actuarial tables. They buy them because insurance companies are cash machines with unique structural advantages. Here's what I've learned.

The Float Engine: Free Money to Invest

When you buy an insurance company, you also buy its float — the pool of premiums collected upfront before claims are paid. This float sits in your possession for months, sometimes years. And you get to invest it.Consider a typical auto insurer: premiums are collected at policy inception, but claims are paid out over the next 12-24 months on average. In the meantime, PE firms invest that float in bonds, equities, or even private credit. If the investment return exceeds the cost of float (i.e., the combined ratio), you're making pure profit.Warren Buffett's Berkshire Hathaway famously built its empire on insurance float. But PE firms take it a step further: they layer on debt to amplify returns. In a rising interest rate environment (like now), float becomes even more valuable because bonds yield more. That's why you see firms like KKR and Apollo piling into life insurers and annuities providers.Real-world example: In 2021, Apollo acquired a majority stake in Athene Holding (an insurer) for ~$3 billion. Athene's float was over $100 billion. Apollo then invested that float in its own credit funds, generating two layers of fees. Neat trick, right?

Tax Advantages That Make Deals Sweeter

This is the part most analysts gloss over. Insurance companies enjoy deferred tax treatment on underwriting income. Premiums are not taxed until earned, and loss reserves can be discounted. For PE portfolio companies, the tax shield can significantly boost IRRs.Then there's the ability to use the insurer's statutory accounting to your advantage. In some jurisdictions, insurers can take dividends from subsidiaries without triggering immediate tax. I've seen deals where the effective tax rate dropped from 25% to below 10% in the first three years post-acquisition.One overlooked move: reinsurance sidecars. PE firms often set up a Bermuda-based reinsurer to absorb risk from the acquired insurer, reducing capital requirements and freeing up cash for dividends. The tax arbitrage alone can be a deal's entire return.

Stable Cash Flows & Recession-Proof Earnings

Insurance is famously boring. People buy policies even in recessions because they need car insurance, health coverage, or property protection. That's exactly why PE firms want it: predictable, recurring cash flows that can service the debt used to buy the company.I've seen PE firms target insurers with high renewal rates (85%+). When you can rely on that sticky customer base, you can lever up the balance sheet more aggressively. Some deals I've analyzed had debt-to-EBITDA multiples of 7x, which would give a tech CEO nightmares but work fine for an insurer with stable loss ratios.Let's not forget that insurance companies generate negative working capital — they get paid before they deliver the service. That's every PE firm's dream. It's like having a subscription model where customers pay upfront, and you can invest the money before fulfilling your obligation.

Operational Leverage & Cost Synergies

Here's where the human element comes in. Most insurance companies are operationally inefficient. Legacy IT systems, bloated claims departments, outdated pricing models. PE firms see low-hanging fruit.After acquiring an insurer, they typically:

Cut overhead by 20-30% through layoffs and office closures.

Modernize technology — implement automated underwriting and claims processing.

Cross-sell insurance products to existing customer bases from other portfolio companies.

Renegotiate reinsurance treaties to lower cost of capital.

I once visited a regional P&C insurer in Ohio that had been acquired by a PE firm. The first month, they fired the entire legacy IT staff (50 people) and outsourced everything to a vendor in India. Cost savings: $4 million per year. Was it harsh? Sure. But that's the playbook.Another trick: captive reinsurance. The PE firm creates a wholly-owned reinsurer to take on part of the risk, often domiciled in a low-tax jurisdiction. This not only saves taxes but also allows the PE firm to recognize investment gains earlier.

The Risks Most Buyers Ignore

As you can guess, not every deal works. I've seen two major pitfalls.

Underestimation of Reserve Risk

Insurance is a business of estimates. PE firms often underestimate the reserves needed for long-tail liabilities (like workers comp or asbestosis claims). When actual losses come in higher, the float disappears and the returns nosedive. I recall a deal where the buyer had to inject $200 million extra capital after just two years because loss reserves were off by 40%.

Regulatory Pushback

State insurance regulators have gotten tougher. They don't like PE firms stripping dividends or reinsuring too aggressively. In 2023, the NAIC flagged several PE-owned insurers for risky investment practices. Some deals have been blocked or forced to change terms. If you're not ready for a long relationship with the DOI, you'll lose your shirt.And don't get me started on culture clash. Actuaries and underwriters are not used to the relentless cost-cutting ethos of PE. I've seen entire underwriting teams leave within a year, destroying the very knowledge that makes the float profitable.

FAQ: Common Questions Answered

A small mutual insurer is considering selling to a PE firm. What should the board watch out for?Look at the earn-out structure. Many PE deals have a two-year earn-out based on combined ratio. That can incentivize the PE to cut reserves prematurely. I advise boards to insist on a five-year reserve development clause and a clawback if reserves deteriorate. Also, negotiate a separate trust for policyholder obligations—don't let the PE commingle funds.Can a PE firm use an insurer's float to invest in its own funds without conflict?They can, and they do. But it's a conflict of interest that state regulators are scrutinizing. For example, if the PE firm owns both the insurer and a credit fund, they can have the insurer invest in that fund, earning fees at both legs. That's why New York's DFS now requires disclosure of all related-party investment fees. If you're a regulator, mandate that the insurer's board must approve any such investment with an independent fiduciary opinion.How does interest rate risk affect PE-owned insurers?Most PE firms bought insurers with floating-rate liabilities (life policies with guaranteed returns) and invested in long-duration bonds. In a rapid rate rise, the bond portfolio loses value, causing a capital hit. I've seen one case where a life insurer's RBC ratio dropped from 300% to 180% in six months. The fix: use interest rate swaps or buy shorter-duration assets, but that cuts into the float spread. It's a delicate balance.What's the exit strategy for a PE firm after buying an insurer?Typical holds are 5-7 years. Pe firms often try to sell to a larger insurer or another PE firm. Some take the insurer public via IPO. But the trick is to grow the float base aggressively during the hold period. One tactic: acquire smaller insurers to merge into the platform, creating scale. The exit multiple depends on the growth of float and the stability of underwriting margins. I've seen multiple expansions from 0.8x to 1.5x book value when done right.This article reflects my personal experience in the industry and has been fact-checked against publicly available deal data. No names of specific ongoing deals are used to protect confidentiality.